Clinical perspectives and therapeutics of thrombolysis.
Reperfusion therapy with thrombolytic agents has been a significant advancement in the management of patients with acute ST elevation myocardial infarction. The outcome of acute myocardial infarction has significantly improved by early application of thrombolytic therapy. Intracoronary streptokinase has been used for >30 years, but reawakening interest occurred in the early 1980s in the use of thrombolytic therapy to establish rapid reperfusion during an acute myocardial infarction. Initial studies aimed at direct intracoronary thrombolysis, but owing to its cumbersome process and requirement of an active round the clock cardiac catheterization laboratory, it has been replaced by regimens of intravenous thrombolytic therapy which is as efficacious as intracoronary administration. Consideration of thrombolytic therapy has become a standard treatment for patients presenting with acute ST elevation myocardial infarction and various well-controlled trials have demonstrated the importance of both early and full reperfusion in improving clinical outcome in the setting of acute myocardial infarction. The subject of intravenous thrombolysis is perhaps the most rapidly evolving area in the management of acute myocardial infarction patients in the past decade. The current review focuses on the thrombolysis in the treatment of myocardial infarction and other conditions.
Khan
Ijaz A
IA
Division of Cardiology, Creighton University School of Medicine, Omaha, NE, USA. ikhan@cardiac.creighton.edu
Gowda
Ramesh M
RM
D002986:Clinical Trials as Topic; D006801:Humans; D009203:Myocardial Infarction / Q000503:physiopathology / Q000628:therapy; D015425:Myocardial Reperfusion; D010960:Plasminogen Activators / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000639:trends; D014481:United States / Q000453:epidemiology
D010960:Plasminogen Activators